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Abstract
Cancer patients have a ~4 fold increased risk of venous thromboembolism (VTE) compared with 
the general population and this is associated with significant morbidity and mortality. This review 
summarizes our current knowledge of VTE and cancer from mouse models to clinical studies. 
Notably, risk of VTE varies depending on the type and stage of cancer. For instance, pancreatic 
and brain cancer patients have a higher risk of VTE than breast and prostate cancer patients. 
Moreover, patients with metastatic disease have a higher risk than those with localized tumors. 
Tumor-derived procoagulant factors and growth factors may directly and indirectly enhance VTE. 
For example, increased levels of circulating tumor-derived, tissue factor-positive microvesicles 
may trigger VTE. In a mouse model of ovarian cancer, tumor-derived IL-6 and hepatic 
thrombopoietin has been linked to increased platelet production and thrombosis. In addition, 
mouse models of mammary and lung cancer showed that tumor-derived granulocyte colony-
stimulating factor causes neutrophilia and activation of neutrophils. Activated neutrophils can 
release neutrophil extracellular traps (NETs) that enhance thrombosis. Cell-free DNA in the blood 
derived from cancer cells, NETs and treatment with cytotoxic drugs can activate the clotting 
cascade. These studies suggest that there are multiple mechanisms for VTE in patients with 
different types of cancer. Preventing and treating VTE in cancer patients is challenging; the 
current recommendations are to use low molecular weight heparin. Understanding the underlying 
mechanisms may allow the development of new therapies to safely prevent VTE in cancer 
patients.
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Introduction
Venous thromboembolism (VTE) causes significant morbidity and mortality in cancer 
patients and the incidence has increased in the past 2 decades [1]. Various studies have 
reported the absolute risk (cumulative incidence) of VTE in cancer patients to be 1-8% [2]. 
It is estimated that cancer patients have a 4 to 7-fold increased risk of VTE compared with 
the general population [2, 3]. VTE also reduce the quality of life of cancer patients and 
potentially interrupt or delay anti-cancer treatments.
The association between cancer and thrombosis was first described in 1823 by Jean-Baptiste 
Bouillard [4]. Later in 1865 a French physician, Armand Trousseau, reported the association 
between gastric cancer and thrombosis [5]. However, it was not until 1935 that thrombosis 
was reported as a first sign of an occult cancer [6]. Current estimates are that 20% to 30% of 
VTEs are associated with cancer [2]. Hospitalized cancer patients with acute medical illness 
or immobility have an increased risk of VTE and receive thromboprophylaxis. In 
ambulatory cancer patients, the overall risk of VTE is lower and no routine 
thromboprophylaxis is recommended. Two recent clinical trials reported the rate of VTE in 
ambulatory patients with solid tumors and receiving chemotherapy was 3.4 and 3.9% [7, 8]. 
This rate is too low to consider routine thromboprophylaxis. However, the risk of VTE is 
increased with certain types of cancer and these patients might benefit from 
thromboprophylaxis [2, 9]. For instance, pancreatic (5.3-26.0%) and brain (1.6-26.0%) 
cancer have the highest rates of VTE, whereas breast (0.4-8.1%) and prostate (0.5-1.4%) 
cancer have the lowest rates of VTE [2, 10]. In addition, patients with metastatic cancer 
have higher rates of VTE than patients with localized cancer [2, 9]. One recent study 
observed a 12.6% rate of VTE (ranging from 8.2% in bladder cancer to 19.2% in pancreatic 
cancer) in high-risk ambulatory cancer patients (lung, ovary, pancreatic and gastric) 3-12 
months after chemotherapy versus 1.4% in non-cancer patients [11].
Cancer patients with VTE have reduced survival compared with patients without VTE 
[12-14]. One study by Khorana and colleagues has the provocative title “thromboembolism 
is a leading cause of death in cancer patients receiving outpatient chemotherapy” [15]. 
Indeed, many papers use this study to support the statement that thrombosis is the second 
leading cause of death in cancer patients. This prospective observational study analyzed 
4466 cancer patients of which 141 (3.2%) died. As expected the leading cause of death was 
the cancer itself (70.9%) followed by thrombosis (9.2%) and infection (9.2%). Only 5 of the 
13 deaths attributed to thrombosis were VTE. However, this study may underestimate VTE 
in cancer patients. In a Swedish autopsy study of in-hospital deaths involving 23796 
between 1970 and 1982 23% of the patients had pulmonary embolism (PE) and 10% of the 
population had a fatal PE [16]. Strikingly, 42% of the pancreatic cancer patients had PE 
[16]. This study indicates a high burden of VTE in cancer patients.
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There are many factors that likely contribute to VTE in cancer patients, such as on tumor 
characteristics, treatment and patient characteristics (Figure 1). The presence of the tumor 
may affect the host coagulation system [17]. Anti-cancer treatments also increase the risk of 
VTE in cancer patients (Figure 1). For instance, surgery increased the risk of VTE in cancer 
patients 2-fold compared with non-cancer patients [18]. Chemotherapy treatment of cancer 
patients has been estimated to further increase the risk of VTE to 6.5-fold compared with the 
general population [2, 19, 20]. The risk of VTE in cancer patients would also be expected to 
be influenced by patient characteristics, such as history of VTE and age (Figure 1). In 
addition, cancer patients with prothrombotic variants, such as factor V Leiden and 
prothrombin G20210, or deficiencies in antithrombin, protein C or protein S, would be 
expected to increase the propensity to develop VTE [21]. Some cancers may increase the 
number of platelets or leukocytes that will increase the risk of VTE. This may explain the 
different rates of VTE associated with different cancers.
This review will summarize the multiple approaches that have been taken to study VTE and 
cancer. They range from basic science studies using mouse models to clinical trials with 
cancer patients and have elucidated a variety of pathways that may contribute to VTE in 
cancer patients (Figure 2). Importantly, information from the different sources needs to be 
integrated into a comprehensive picture of cancer-associated VTE.
Biomarkers of a hypercoagulable state in cancer patients
There are a number of biomarkers that have been reported in cancer-associated VTE [22]. 
We will initially discuss biomarkers of a hypercoagulable state [23, 24]. Activation of the 
coagulation system in cancer patients means that any insult that triggers clotting is more 
likely to result in pathological thrombosis. Biomarkers of a hypercoagulable state include 
thrombin-antithombin complexes (TATc), prothrombin fragment 1 + 2 (F1 + 2) and factor 
VIII. In addition, D-dimer is a fibrin degradation product that is used as a biomarker of 
ongoing activation of coagulation. The Pabinger group has measured many different 
biomarkers of a hypercoagulable state in patients with different types of cancer enrolled in 
the Vienna Cancer and Thrombosis Study (CATS) to determine which ones can be used to 
predict VTE [25].
D-dimer is probably the most robust measure of a hypercoagulable state and is used 
clinically in the work-up of a suspected VTE. One problem with D-dimer is that the 
specificity is decreased in older individuals and there are a number of different commercial 
assays with varying sensitivities and specificities [26]. Kodama and colleagues measured 
plasma D-dimer in 267 gynecologic cancer patients 3 days after surgery and found that the 
median value of D-dimer for VTE-positive patients (7.1 μg/mL) was significantly higher 
than that for VTE-negative patients (4.7 μg/mL) (P = 0.009) [27]. Stender and colleagues 
measured the preoperative plasma D-dimer level of 176 colorectal cancer patients and found 
that patients with a D-dimer >0.3 μg/mL (43% of the patients) had a significantly higher risk 
of deep vein thrombosis (DVT) than patients D-dimer <0.3 μg/mL (P = 0.009) [28]. In the 
Vienna CATS that analyzed many different types of cancers a D-dimer ≥1.44 μg/mL was 
associated with a higher incidence of VTE [29].
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One study found that pre-surgery levels of TATc in the plasma of abdominal cancer patients 
undergoing surgery correlated with postoperative DVT [30]. In the Vienna CATS, an 
elevated level of F1 + 2 was an independent risk factor for VTE in cancer patients (>358 
pmol/L) [29]. Furthermore, patients with elevated levels of both D-dimer and F1 + 2 had the 
highest hazard ratio for VTE [29]. FVIII activity was also identified as an independent risk 
factor for VTE in cancer patients [31]. During a 6 month follow up, 14% patients with 
elevated levels of FVIII activity had a VTE compared with 4% in those with normal FVIII 
activity (P = 0.001). These studies indicate that biomarkers of a hypercoagulable state are 
associated with VTE in patients with different types of cancer.
Tumor cell tissue factor and tumor-derived tissue factor-positive MVs
Many tumors express tissue factor (TF) and release TF+ microvesicles (MVs) in the 
circulation (Figure 2) [32, 33]. MVs are small membrane vesicles that are derived from the 
plasma membrane. Tumors derived from epithelial tissue often express very high levels of 
TF, particularly pancreatic adenocarcinomas [34-36]. We found that mice bearing TF-
expressing human pancreatic tumors but not TF-negative tumors had systemic activation of 
coagulation that was abolished by inhibition of tumor-derived human TF [37]. Consistent 
with the notion that tumor cell TF contributes to thrombosis, a high level of TF expression in 
biopsy samples from ovarian, pancreatic and brain cancer patients is associated with an 
increase in the rate of VTE [35, 38, 39]. However, a more recent study did not find that TF 
expression in brain tumors was associated with future VTE [39].
Cultured TF-expressing cancer cells release TF+ MVs into the culture supernatant and TF-
expressing tumors release TF+ MVs into the blood [37, 40-42]. One study using the mouse 
pancreatic adenocarcinoma cell line Panc02 found that tumor-derived MVs accumulate at 
sites of vascular injury, and that tumor-bearing mice had reduced occlusion times in 
mesenteric vessels injured with ferric chloride [43]. We found that injection of TF+ MVs 
from a human pancreatic cell line increased venous thrombosis in mice [37], and that this 
enhancement was abolished by inhibition of TF (Geddings and Mackman, unpublished 
data).
MV TF activity has been measured the plasma in a variety of cancer patients. These in-
house assays should be viewed as semiquantitative. One general conclusion from these 
studies is that pancreatic cancer patients have the highest levels of MV TF activity [33]. For 
instance, one study measured levels of MV TF activity in pancreatic, brain, gastric and 
colorectal cancer patients because these cancers are associated with a high risk of VTE [44]. 
The highest levels of MV TF activity were observed in pancreatic cancer patients (mean 
value of MV TF activity: pancreatic 0.10 pg/mL; stomach 0.07 pg/mL; colorectal 0.05 
pg/mL; brain 0.04 pg/mL). A second observation is that MV TF activity in pancreatic cancer 
patients is associated with VTE but not other types of cancers [33]. At present, it is unclear 
why the highest levels of MV TF activity are observed in pancreatic cancer patients, and that 
this activity correlated with VTE in pancreatic cancer patients but not other types of cancers. 
This may reflect a high level of TF expression in pancreatic tumors relative to other tumors, 
and that pancreatic cancer is often detected at a later stage than other cancers. Taken 
together, these studies suggest that MV TF plays a role in VTE in pancreatic cancer patients.
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We speculate that TF+ MVs may contribute to VTE in cancer patients via both direct and 
indirect pathways (Figure 3). For instance, TF+ MVs may directly trigger VTE by binding to 
activated endothelium or activate other cells, such as platelets. Recently, we found that TF+ 
MVs from two human pancreatic cell lines bind to platelets and activate them by generating 
thrombin (Geddings J and Mackman N, unpublished data). The notion that tumor-derived 
TF+ MVs may activate platelets was proposed in a recent review [45]. Further studies are 
needed to determine the mechanisms by which tumor-derived TF+ MVs enhance VTE in 
mouse models and in cancer patients.
Role of platelets in VTE in cancer patients
Platelets have been shown to play a role in cancer by increasing tumor growth, metastasis 
and thrombosis [46, 47]. Cancer patients often have low platelet counts due to the 
chemotherapy. However, in a subset of patients the presence of the tumor appears to 
increase the number of platelets. Khorana and colleagues were the first group to describe an 
association between a high platelet count and VTE in ~3000 ambulatory cancer patients 
beginning chemotherapy [48]. The rate of VTE in patients with platelet counts ≥350,000/μL 
(21.7% of the patients) measured prior to chemotherapy was 4% compared with 1.2% in 
patients with a platelet count <200,000/μL (P = 0.0003). Similarly, patients in the Vienna 
CATS with a high platelet count (>443,000/μL) (5% of the patients) had a 1 year cumulative 
rate of VTE of 34.3% compared with 5.9% in all other patients [49]. Finally, the Tromsø 
group measured platelet counts in people prior to the development of cancer and found that 
cancer patients with a platelet count greater than the 80th percentile (>295,000/μL) had a 2-
fold increased risk of VTE compared with cancer patients with platelet counts below the 
40th percentile (235,000/μL) [50]. This indicates that people with naturally high platelet 
counts that develop cancer have a higher risk of VTE. In a mouse study, it was reported that 
ovarian tumors induced thrombocytosis by releasing IL-6 that stimulates hepatic 
thrombopoietin expression [51]. Interestingly, increased levels of plasma von Willebrand 
factor have been reported in patients with ovarian, bladder, and colon cancers [52]. These 
studies suggest that platelets contribute to the pathophysiology of VTE in cancer patients.
Biomarkers of platelet activation
Several different groups have measured a variety of biomarkers of platelet activation in 
cancer patients [47]. These biomarkers include P-selectin, soluble CD40 ligand, platelet 
factor-4, thrombospondin-1 and β-thromboglobulin. Most of these biomarkers were found to 
be elevated in a variety of cancer patients [47]. However, few studies have determined if 
elevated levels of these platelet biomarkers predict VTE in cancer patients.
P-selectin is a transmembrane adhesion molecule expressed on activated platelets and 
endothelial cells [53]. In the Vienna CATS, an elevated level of soluble P-selectin (sP-
selectin) was identified as a risk factor for VTE in cancer patients [54]. Patients with a high 
level of sP-selectin (> 53.1 ng/mL) had a 2.6-fold increase in risk of VTE compared with 
cancer patients with a low level of sP-selectin (< 53.1 ng/mL) (P = 0.003) [55]. Another 
study found that the odd ratio for the development of VTE was ~3 in pancreatic cancer 
patients with high platelet factor-4 levels [56]. A recent study measured a variety of platelet 
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activation markers in 1779 patients with different types of cancer [57]. The study confirmed 
that sP-selectin was associated with VTE in cancer patients but no association was found for 
soluble CD40 ligand, thrombospondin-1 and platelet factor-4 [57]. These differences could 
be due to the sensitivity of the different assays and/or that endothelial cells are a source of 
plasma sP-selectin in cancer patients. These studies provide further evidence suggesting that 
platelets are activated in cancer patients and likely contribute to VTE, although the relative 
risk for VTE associated with these markers is relatively low.
Role of leukocytes in VTE in cancer patients
Leukocyte counts are frequently elevated in cancer patients [58]. Khorana and colleagues 
first described a relationship between leukocytosis at the time of diagnosis and VTE in 
cancer patients [59]. They found a 2.2-fold increased risk of VTE in patients with a high 
leukocyte count (>11 × 109 cells/L) compared with patients with a low leukocyte count. In 
the Vienna CATS, leukocyte count was also identified as an independent risk factor for 
thrombosis in cancer patients [60]. Leukocytosis is also associated with VTE in brain tumor 
patients [61]. Finally, a study by Blix and colleagues in Tromsø found that cancer patients 
with a high pre-cancer leukocyte count (≥8.6 × 109 cells/L) (20% of the patients) had a 2.4-
fold higher risk of VTE than those with a lower leukocyte count (<6.4×109 cells/L) [62]. 
Leukocytosis is also related to poor prognosis in cancer patients [63]. Connolly and 
colleagues performed a multicenter observational study evaluating the relationship between 
leukocytosis, VTE and mortality in cancer patients starting chemotherapy. The mortality 
rates of patients with VTE only or leukocytosis only were 2.9% or 6.9%, respectively, 
whereas those with both leukocytosis and VTE had a mortality rate of 20% [63]. These 
studies indicate that cancer patients with a high leukocyte count due to either their genetics 
or the presence of the tumor have a higher risk for VTE.
Leukocytes have been shown to play a role in animal models of venous thrombosis but do 
not appear to be necessary for hemostasis [64]. Leukocytes activate the coagulation cascade 
as part of the innate immune response to infection to prevent the spread of a pathogen. 
However, unlike hemostasis that must occur rapidly, leukocyte-induced activation of 
coagulation may take several hours. For instance, the maximal levels of TF are observed in 
monocytes 6 hours after LPS stimulation. In venous thrombosis, leukocytes appear to be 
activated by host factors in the absence of a pathogen. Neutrophils are the most abundant 
white blood cell and levels increase during infection. Release of the neutrophil proteases 
elastase and cathepsin G has been shown to activate platelets by cleavage of Par4, and to 
activate the coagulation cascade by inactivation of the anticoagulant protein tissue factor 
pathway inhibitor [65]. In a mouse model of venous thrombosis both neutrophils and 
monocytes were recruited at the site of thrombosis and both cell types appeared to express 
TF [64]. Importantly, depletion of neutrophils reduced thrombosis in this model [64]. Taken 
together, these studies suggest that leukocytes actively contribute to VTE in cancer patients.
Neutrophil extracellular traps (NETs)
Highly activated neutrophils release neutrophil extracellular traps (NETs) via a process 
called NETosis [66, 67]. This process requires the enzyme peptidylarginine deiminase 4 
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(PAD4), which converts arginine residues to citrulline on the histone tail. Therefore, the best 
biomarker of NETs is hypercitrullinated histone H3. NETs are composed of extracellular 
DNA fibers, histones and granular proteins that have been shown to play a role in innate 
immunity by enhancing the proteolysis and killing of bacteria [68, 69].
Recently, it was reported that NETs enhance clot formation in vitro and in vivo [70-72]. 
NETs promoted erythrocyte-rich thrombus formation and platelet aggregation in vitro [70]. 
In addition, NETs contribute to venous thrombosis in a mouse model [71, 72]. Importantly, 
mice lacking the ability to make NETs due to a deficiency in PAD4 had smaller thrombi 
compared with controls [73]. Finally, NETs have been observed in human VTE [74].
Do NETs contribute to cancer-associated thrombosis? Demers and colleagues investigated 
the role of NETs in lung thrombosis in two mouse tumor models: 4T1 mammary tumors 
grown in BALB/c mice and Lewis lung carcinoma tumors grown in C57Bl/6 mice [75]. 
They found that both types of tumors were associated with an increase in the number of 
peripheral blood neutrophils, and that the neutrophils in tumor-bearing mice were more 
prone to NETosis. In the 4T1 model, tumor-derived granulocyte colony-stimulating factor 
(G-CSF) was responsible for the neutrophilia and sensitization of the neutrophils to NETosis 
[75]. There was also an increase in plasma DNA that appears to originate, in part, from 
activated neutrophils. Finally, hypercitrullinated histone H3 was detected in thrombi in the 
lungs of tumor-bearing mice. These results suggest that NETs contribute to thrombosis in 
mouse models of cancer (Figure 2) [76, 77]. Although high levels of cell-free DNA in the 
plasma of cancer patients has been well described for many years, the levels of NETs in 
cancer patients or its participation in coagulation have not been reported. Therefore, further 
studies are needed to define the role of neutrophils and NETs in VTE in cancer patients. One 
study concluded that “the current enthusiasm about NETs in cancer is not yet supported by 
clinical data” [60].
Cell-free DNA
Neutrophils are not the only source of cell-free DNA in plasma. Tumor cells release various 
nucleic acids, such as DNA, mRNA and microRNA, and cancer patients have an elevated 
level of cell-free DNA in their blood [78]. Levels of cell-free DNA in the blood also 
increase with tumor burden and malignancy. DNA and RNA have been reported to activate 
factor XII, although this remains somewhat controversial (Figure 2) [79]. In addition, 
administration of chemotherapy may increase levels of cell-free DNA in the blood. For 
instance, Swystun and colleagues found that administration of various chemotherapeutic 
agents to mice increased levels of cell-free DNA in the plasma and activated coagulation 
[80]. In addition, they detected elevated levels of cell-free DNA in breast cancer patients 24 
hours after administration of chemotherapy. Although Swystun and colleagues showed that 
cell-free DNA induced thrombin generation in an FXIIa-dependent manner in vitro, no 
studies were performed to determine the role of FXII in the activation of coagulation in mice 
treated with chemotherapeutic agents [80]. These results suggest that cell-free DNA in the 
blood of cancer patients is a prothrombotic stimulus that contributes to VTE.
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Risk assessment models have been developed to predict the risk of VTE in the general 
population. One of these models is the Padua Prediction Score, which was developed to 
determine which hospital inpatients would benefit from thromboprophylaxis [81]. Clinical 
indicators are given a different number of points depending on their relative importance in 
the prediction of future VTE. Importantly, active cancer (“patients with local or distant 
metastasis and/or in whom chemotherapy or radiotherapy had been performed in the 
previous 6 months”) is considered a high risk factor. Khorana and colleagues developed a 
risk assessment model for predicting VTE in ambulatory cancer patients that is known as the 
“Khorana score” [59]. There are five clinically available factors that are assessed: site of 
cancer, erythropoiesis stimulating agents, platelet count, leukocyte count, and body mass 
index. Based on the different rates of VTE associated with different cancer types, the 
Khorana score designates pancreas and stomach as “very high risk”, whereas lung, 
lymphoma, gynecologic cancers and genitourinary (excluding prostate) are designated “high 
risk”. Breast and colorectal cancer are considered low risk and brain cancer was not included 
in the analysis. The score is used to divide patients into 3 risk categories for a predicted rate 
of VTE over a 2.5 month period: low (0 points) (0.3-0.8% VTE), intermediate (1-2 points) 
(1.8-2.0% VTE), and high (≥ 3 points) (6.7-7.1% VTE). It should be noted that the 
percentage of patients in the “high-risk” group was 10.9% and 12.6% for the validation and 
derivative cohorts, respectively. Interestingly, thrombocytosis is also included in a risk 
assessment model for VTE in medical inpatients [82].
Recently, Ay and colleagues extended the Khorana score by adding brain cancer to the very 
high risk cancer site and the biomarkers D-dimer and sP-selectin and called this the Vienna 
score [54]. Of note s-P-selectin is not available to most clinicians. A total of 819 cancer 
patients were analyzed for 6 months for VTE and divided into 4 categories based on their 
score: 0 points (1.5% VTE), 1 point (3.8% VTE), 2 points (9.6% VTE), ≥3 (17.7% VTE). 
Again, it should be noted that only 11.4% of the patients were at “high-risk”. A risk 
assessment model has also been developed to assess the risk of recurrent VTE in cancer 
patients called the Ottawa score [83]. This model uses 4 patient characteristics that are 
proposed to increase the risk of VTE: female sex, history of VTE, cancer type and late stage. 
The rate of VTE in patients with a score of 1-3 was 13.8-17.5% compared with 3-5.6% for 
those with a score of 0. These risk assessment models are designed to identify ambulatory 
cancer patients at high risk for primary and recurrent VTE that would benefit from 
thromboprophylaxis.
Use of the Khorana score has been recommended by the American Society of Clinical 
Oncology to guide VTE prophylaxis in cancer patients [84, 85]. However, only ~10% of the 
ambulatory cancer patients receiving chemotherapy are categorized as “high-risk” using the 
Khorana score and within this group only ~7% of the patients develop VTE within the first 
2.5 months. This may explain why clinical oncologists are not screening their patients for 
risk of VTE.
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Prevention of VTE in cancer patients
Low molecular weight heparin
Low molecular weight heparins (LMWH) are a mainstay of anticoagulant therapy. In 
addition to their anticoagulant activity, they have been proposed to have anti-tumoral 
activity. This has led to several clinical trials that determined the effect of various LMWHs 
on survival of cancer patients. This topic has been recently reviewed by Franchini and 
Mannucci [86]. We will focus on those studies that investigating LMWH for prevention of 
VTE in cancer patients receiving chemotherapy as outpatients. The PROTECHT study 
enrolled 1150 ambulatory patients with lung, gastrointestinal, pancreatic, breast, ovarian and 
head and neck cancers. Patients were randomized to receive placebo (n = 779) or the 
LMWH nadroparin (n = 387) daily for 4 months. Nadroparin significantly reduced the rates 
of VTE from 3.9% to 2.0% but did not prolong survival [7]. The SAVE-ONCO study 
enrolled 3212 patients with locally advanced or metastatic cancer and randomized them to 
receive placebo (n = 1604) or the LMWH semuloparin (n = 1608) daily for a median 
duration of 3.5 months. Similar to the PROTECT study, semuloparin significantly reduced 
VTE from 3.4% to 1.2% (p = 0.001) but again did not affect survival [8]. 
Thromboprophylaxis with semuloparin did not increase major bleeding. In TOPIC I and 
TOPIC II patients with disseminated metastatic breast cancer or stage III/IV non-small-cell 
lung cancer received the LMWH certoparin daily for 6 months but this did not change the 
rate of VTE or survival [87]. One study randomized 123 patients with advanced pancreatic 
cancer to receive either placebo or the LMWH dalteparin for 3 months and found a striking 
reduction in VTE in the patients receiving dalteparin (23% versus 3.4%, p = 0.02) [88]. 
Despite the reduction in VTE dalteparin did no prolong survival of the pancreatic cancer 
patients, which is likely due to the fact that the study was underpowered to show an effect 
on survival [88]. Finally, PROSPECT-CONKO 004 was a prospective, randomized trial to 
assess the effect of the LMWH enoxaparin on VTE in advanced pancreatic cancer patients 
[89]. Enoxaparin reduced VTE from 14.5% (22/152 patients) to 5.0% (8/160 patients) with 
no increase in major bleeding or survival. It should be mentioned that higher doses of 
dalteparin and enoxaparin were used for primary thromboprophylaxis in the latter two 
studies. Taken together, these results indicate that LMWHs are effective in reducing VTE in 
cancer patients, particularly in high-risk cancer patients. Although these trials do not report 
an increase in bleeding in the cancer patients receiving LMWH this would be a concern in 
this group of patients [90]. VTE has been estimated to be the cause of death of ~3.3% of 
patients [15]. Therefore, it is not surprising that reducing VTE in cancer patients did not 
improve survival, although post mortem autopsy studies are needed to more reliably 
quantify VTE as an underlying cause of death.
Anti-platelet drugs
Traditionally, platelets have not been thought to play a major role in VTE and antiplatelet 
drugs are not used to prevent or treat VTE. However, recent basic and clinical studies have 
shown that platelets contribute to VTE. For instance, a meta-analysis of two large clinical 
trials showed that low dose aspirin significantly reduces recurrent VTE when administered 
after the completion of a 6-18 month period of oral anticoagulation with a vitamin K 
antagonist (VKA) [91]. In mouse models depletion of platelets or a deficiency of von 
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Willebrand factor significantly reduced the size of venous thrombi suggesting that platelets 
may contribute to VTE in patients [64, 92]. Two retrospective studies analyzed the effect of 
aspirin on VTE in breast and ovarian cancer patients and found no difference in breast 
cancer and a “marginally significant reduction” with ovarian cancer patients (P = 0.053) [93, 
94]. However, low dose aspirin was found to be as effective as LMWH in reducing VTE in 
multiple myeloma patients treated with either thalidomide or lenalidomide [95, 96]. In a 
mouse model of pancreatic cancer inhibition of platelet activation prevented accumulation of 
tumor-derived MVs at the site of thrombosis [97]. We found that inhibition of platelet 
activation with clopidogrel abolished the ability of exogenous tumor-derived TF+ MVs to 
enhance venous thrombosis in mice (Geddings and Mackman, unpublished data). These data 
suggest that anti-platelet drugs may reduce VTE in cancer patients. A recent review on the 
role of platelets in cancer-associated thrombosis concluded that “while platelet inhibitory 
agents might be considered in the prevention of VTE, there is no obvious indication for 
platelet inhibition in the treatment of VTE” [47].
Statins
Statins have been proposed to reduce VTE. However, meta-analysis of 22 trials did not find 
a significant effect of statins on VTE in the general population [98]. Two studies have 
determined the effect of statins on VTE in cancer patients. The first analyzed retrospectively 
740 cancer patients and found that 21% of the patients who were not on a statin had a VTE 
(n = 116) whereas only 8% of the patients taking statins had a VTE [99]. A less dramatic 
difference was observed in a prospective study that included 729 cancer patients; VTE was 
observed in 8.1% of the patients without statins versus 3.5% of the patients with statins 
[100]. It is unclear if the differences are large enough to warrant randomized clinical trials of 
statins for primary thromboprohylaxis in cancer patients.
Treatment of VTE in cancer patients.
Standard treatment of acute VTE event in the general population consists of initial treatment 
with fast acting LMWH together with a VKA. Once the VKA is in the therapeutic range, the 
LMWH can be stopped. Direct oral anticoagulant drugs (DOACs) that target either factor 
Xa or thrombin are fast acting and can be used without overlapping LMWH treatment. Lee 
and Peterson recently reviewed the treatment of VTE in cancer patients [101]. Interestingly, 
meta-analysis of open-label, randomized controlled trials showed improved efficacy of 
different LMWHs versus VKAs for the treatment and prevention of recurrent VTE in cancer 
patients. It is unclear why LMWHs are more effective than VKAs in preventing recurrent 
VTE in cancer patients but suggests that different thrombotic mechanisms may be in play. 
Analysis of the recent DOAC clinical trials showed that they were comparable to VKAs in 
preventing recurrent VTE [102]. However, randomized controlled trials are needed to 
determine the effectiveness and safety of DOACs compared with LMWHs in preventing 
recurrent VTE in cancer patients.
Conclusion
Cancer-associated thrombosis increases morbidity and mortality in patients. The occurrence 
of VTE is likely triggered by multiple pathways in different cancer patients. Further studies 
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are needed to determine the relative contributions of these different pathways in VTE 
associated with different cancer types. The National Heart, Lung and Blood Institute and the 
National Cancer Institute held a Cancer and Thrombosis Workshop in August 2014 to 
discuss cancer-associated thrombosis (http://www.nhlbi.nih.gov/research/reports/national-
heart-lung-and-blood-institute-nhlbi-national-cancer-institute-nci-cancer-and-thrombosis). 
This joint initiative between two National Institutes of Health Institutes should stimulate 
new research into the mechanisms of cancer-associated thrombosis and the prevention and 
treatment of thrombosis in cancer patients. These and other studies may identify new targets 
that can be used to develop novel antithrombotic drugs that can be safely used in cancer 
patients.
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Figure 1. Risk factors of cancer-associated thrombosis
Tumor characteristics and treatment can contribute to VTE in cancer patients. The tumor 
may also release growth factors that elevate the platelet and leukocyte counts contributing to 
increased risk of thrombosis. Finally, patient characteristics and prothrombotic mutations 
could combine with tumor-specific factors to increase the risk of venous thrombosis.
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Figure 2. Mechanisms of cancer-associated thrombosis
Tumors release cell-free DNA, procoagulant factors and growth factors that enhance venous 
thrombosis. These include tissue factor (TF)-positive microvesicles, IL-6, thrombopoietin 
(TPO) and granulocyte colony-stimulating factor (G-CSF). Release of neutrophil 
extracellular traps (NETs) from neutrophils and tissue factor expression by monocytes 
enhance thrombosis. Chemotherapy and other drugs used to treat cancer patients may 
damage the endothelium and increase levels of cell-free DNA in the plasma.
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Figure 3. Tissue factor (TF)-positive tumor microvesicles may enhance venous thrombosis via 
different pathways
Tumor microvesicles (TMV) may bind to activate the endothelium bind to activate 
endothelium. TMV may bind to platelets and activate them in a thrombin-dependent 
manner. TMV may bind to monocytes and induce TF expression. Finally, TMV may 
enhance the release of neutrophil extracellular traps (NETs) from neutrophils.
Hisada et al. Page 20
J Thromb Haemost. Author manuscript; available in PMC 2016 March 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
